Publicaciones en colaboración con investigadores/as de University of Texas Southwestern Medical Center (12)

2024

  1. Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522

    Annals of Oncology

2023

  1. Pembrolizumab Plus Chemotherapy Followed by Pembrolizumab in Patients With Early Triple-Negative Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial

    JAMA network open, Vol. 6, Núm. 11, pp. e2342107

2022

  1. Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer

    New England Journal of Medicine, Vol. 386, Núm. 6, pp. 556-567

2020

  1. Epilepsy and Electroencephalographic Abnormalities in SATB2-Associated Syndrome

    Pediatric Neurology, Vol. 112, pp. 94-100

2019

  1. A Summary of the Fight Colorectal Cancer Working Meeting: Exploring Risk Factors and Etiology of Sporadic Early-Age Onset Colorectal Cancer

    Gastroenterology, Vol. 157, Núm. 2, pp. 280-288

  2. Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: A post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial

    Cardiovascular Diabetology, Vol. 18, Núm. 1

  3. Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1–7 trials

    Diabetes and Metabolism, Vol. 45, Núm. 5, pp. 409-418

2018

  1. Insulin degludec/liraglutide (IDegLira) was effective across a range of dysglycaemia and body mass index categories in the DUAL V randomized trial

    Diabetes, Obesity and Metabolism, Vol. 20, Núm. 1, pp. 200-205

2017

  1. Insulin regulates astrocytic glucose handling through cooperation with IGF-I

    Diabetes, Vol. 66, Núm. 1, pp. 64-74

2016

  1. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes

    New England Journal of Medicine, Vol. 375, Núm. 19, pp. 1834-1844

2015

  1. Candida infective endocarditis: An observational cohort study with a focus on therapy

    Antimicrobial Agents and Chemotherapy, Vol. 59, Núm. 4, pp. 2365-2373

  2. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes

    New England Journal of Medicine, Vol. 373, Núm. 3, pp. 232-242